Kämpgen E - Search Results

1

Longitudinal analysis of MART-1/HLA-A2-reactive T cells over the course of melanoma progression.

Terheyden P, Schrama D, Pedersen LØ, Andersen MH, Kämpgen E, thor Straten P, Becker JC. Terheyden P, et al. Among authors: kampgen e. Scand J Immunol. 2003 Nov;58(5):566-71. doi: 10.1046/j.1365-3083.2003.01324.x. Scand J Immunol. 2003. PMID: 14629628 Free article.

2

Characterization of mouse MAGE-derived H-2Kb-restricted CTL epitopes.

Eggert AO, Andersen MH, Voigt H, Schrama D, Kämpgen E, Straten PT, Becker JC. Eggert AO, et al. Among authors: kampgen e. Eur J Immunol. 2004 Nov;34(11):3285-90. doi: 10.1002/eji.200324618. Eur J Immunol. 2004. PMID: 15384049 Free article.

3

CD40-ligated dendritic cells effectively expand melanoma-specific CD8+ CTLs and CD4+ IFN-gamma-producing T cells from tumor-infiltrating lymphocytes.

Terheyden P, Straten P, Bröcker EB, Kämpgen E, Becker JC. Terheyden P, et al. Among authors: kampgen e. J Immunol. 2000 Jun 15;164(12):6633-9. doi: 10.4049/jimmunol.164.12.6633. J Immunol. 2000. PMID: 10843723

4

Classical chemotherapy for metastatic melanoma.

Becker JC, Kämpgen E, Bröcker E. Becker JC, et al. Among authors: kampgen e. Clin Exp Dermatol. 2000 Sep;25(6):503-8. doi: 10.1046/j.1365-2230.2000.00690.x. Clin Exp Dermatol. 2000. PMID: 11044186 Review.

5

Sequential interferon-alpha2b, interleukin-2 and fotemustine for patients with metastatic melanoma.

Terheyden P, Becker JC, Kämpgen E, Bröcker EB. Terheyden P, et al. Among authors: kampgen e. Melanoma Res. 2000 Oct;10(5):475-82. doi: 10.1097/00008390-200010000-00010. Melanoma Res. 2000. PMID: 11095409 Clinical Trial.

6

Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: cessation of CTL responses is associated with disease progression.

Andersen MH, Keikavoussi P, Bröcker EB, Schuler-Thurner B, Jonassen M, Søndergaard I, Straten PT, Becker JC, Kämpgen E. Andersen MH, et al. Among authors: kampgen e. Int J Cancer. 2001 Dec 15;94(6):820-4. doi: 10.1002/ijc.1536. Int J Cancer. 2001. PMID: 11745484

7

Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2.

Becker JC, Terheyden P, Kämpgen E, Wagner S, Neumann C, Schadendorf D, Steinmann A, Wittenberg G, Lieb W, Bröcker EB. Becker JC, et al. Among authors: kampgen e. Br J Cancer. 2002 Oct 7;87(8):840-5. doi: 10.1038/sj.bjc.6600521. Br J Cancer. 2002. PMID: 12373596 Free PMC article. Clinical Trial.

8

[Immunochemotherapy of metastatic uveal melanoma with interferon alfa-2b, interleukin-2 and fotemustine. Case reports and review of the literature].

Terheyden P, Kämpgen E, Rünger TM, Bröcker EB, Becker JC. Terheyden P, et al. Among authors: kampgen e. Hautarzt. 1998 Oct;49(10):770-3. doi: 10.1007/s001050050823. Hautarzt. 1998. PMID: 9857252 Review. German.

9

Predominant expression of Fas (CD95) ligand in metastatic melanoma revealed by longitudinal analysis.

Terheyden P, Siedel C, Merkel A, Kämpgen E, Bröcker EB, Becker JC. Terheyden P, et al. Among authors: kampgen e. J Invest Dermatol. 1999 Jun;112(6):899-902. doi: 10.1046/j.1523-1747.1999.00607.x. J Invest Dermatol. 1999. PMID: 10383736 Free article.

10

[Nevus of Ota and choroid melanoma].

Terheyden P, Rickert S, Kämpgen E, Münnich S, Hofmann UB, Bröcker EB, Becker JC. Terheyden P, et al. Among authors: kampgen e. Hautarzt. 2001 Sep;52(9):803-6. doi: 10.1007/s001050170070. Hautarzt. 2001. PMID: 11572072 German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

92 results

Search Page

Filters